(Reuters) -Britain's Avacta Group is halting sales of its COVID-19 rapid antigen lateral flow test to replace antibodies in the device and boost its ability to detect the Omicron variant, the biotech ...

As a result of the rapidly-spreading Omicron variant, Covid case numbers have continued to rise across the UK in record numbers, with 120,821 new cases reported in the last 24 hours. Now, the prime ...

Can you test positive for covid-19 without being infectious? Even if you have had three doses of coronavirus vaccine, a positive lateral flow test (LFT) result means you are infectious to other people ...

As the omicron variant has created a new wave of cases around the country, a corresponding appetite for COVID testing has emerged as well. As has been the case with so much of the pandemic, there's a ...

A recent study published on the medRxiv* preprint server discusses the role of lateral flow device (LFD) testing in potentially improving coronavirus disease 2019 (COVID-19) isolation policies. Study: ...

A mass testing programme in the Liverpool region led to a 32 per cent reduction in hospitalisations from coronavirus, a study suggests. A new report into the city’s project, which saw residents ...

Avacta to replace antibodies in AffiDX test Finds test is less sensitive to Omicron at lower viral loads No timeline for sales resumption, shares plunge 26.5% Jan 10 (Reuters) - Britain's Avacta Group ...

British biotech firm Avacta Group said on Monday it was halting sales of its COVID-19 antigen lateral flow test, AffiDX, to replace antibodies in the device and boost its ability to detect the Omicron ...